Alzheimer's Disease Clinical Trials in Los Angeles

Showing 41-60 of 175 trials

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

NCT04500847

This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months to complete all procedures for the month 6 study visit.

Alzheimer Disease, Early OnsetMild Cognitive ImpairmentModerate Dementia

Butler Hospital35 participantsStarted Dec 2021

Los Angeles, California, United States • Providence, Rhode Island, United States

TERMINATEDPhase 3< 1 mile

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

NCT05310071

The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.

Alzheimer's Disease

Biogen1,027 participantsStarted Jun 2022

Gilbert, Arizona, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +262 more locations

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Alzheimer's Disease Trials in Other Cities

Cardiac-Control Affecting Learning Through Mindfulness (CALM)

Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium

RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

North American Prodromal Synucleinopathy Consortium

An Electronic Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions

Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Goals of Care Conversations Study

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

The PREVENTION Trial: Precision Recommendations to Optimize Neurocognition

Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

Salsalate in Patients Mild to Moderate Alzheimer's Disease

Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test

Other Conditions in Los Angeles